Format
Sort by

Send to

Choose Destination

Selected items

Items: 5

1.

Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Desta Z, Zhao X, Shin JG, Flockhart DA.

Clin Pharmacokinet. 2002;41(12):913-58. Review.

PMID:
12222994
2.

Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.

Coller JK, Somogyi AA, Bochner F.

Br J Clin Pharmacol. 1999 Aug;48(2):158-67.

3.

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA.

J Pharmacol Exp Ther. 1999 Aug;290(2):635-40.

PMID:
10411572
4.

In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes.

Lu AH, Shu Y, Huang SL, Wang W, Ou-Yang DS, Zhou HH.

Acta Pharmacol Sin. 2000 Aug;21(8):747-52.

5.

Polymorphic oxidative metabolism of proguanil in a Nigerian population.

Bolaji OO, Sadare IO, Babalola CP, Ogunbona FA.

Eur J Clin Pharmacol. 2002 Nov;58(8):543-5. Epub 2002 Sep 24.

PMID:
12451432

Supplemental Content

Support Center